Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy
Purpose : A prospective Phase II trial was carried out to evaluate the effectiveness of erythropoietin in improving or maintaining performance status as determined by the Karnofsky performance status (KPS) score and hemoglobin (Hb) levels in lung cancer patients treated with concurrent chemoradiatio...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2003, Vol.55 (1), p.116-124 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 124 |
|---|---|
| container_issue | 1 |
| container_start_page | 116 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 55 |
| creator | Casas, Francesc Viñolas, Núria Ferrer, Ferran Farrús, Blanca Gimferrer, Josep Maria Agustı́, Carles Belda, Josep Luburich, Patricio |
| description | Purpose
: A prospective Phase II trial was carried out to evaluate the effectiveness of erythropoietin in improving or maintaining performance status as determined by the Karnofsky performance status (KPS) score and hemoglobin (Hb) levels in lung cancer patients treated with concurrent chemoradiation (CH-RT).
Methods and Materials
: A total of 51 patients with lung cancer (11 with small-cell, limited stage and 40 with non-small-cell disease, 17 with Stage IIIA and 23 with Stage IIIB), who underwent three different concurrent CH-RT protocols were enrolled. Baseline Hb and KPS values were recorded, as were the nadir Hb and KPS values before concurrent CH-RT. The final Hb and KPS values were recorded the last week of concurrent CH-RT. An Hb level of ≤11 g/dL before concurrent CH-RT was required before receiving erythropoietin. Prognostic factors for KPS improvement and survival were assessed by univariate and multivariate studies.
Results
: Of the 51 patients, 47 (92.3%) were men (mean age 63.6 years, range 40–75). The median baseline KPS score was 80, and the mean baseline Hb was 12.2 ± 1.76 g/dL (range 9–16.9). The mean nadir and final Hb value was 9.98 ± 0.67 g/dL (range 8.6–11) and 11.33 ± 1.59 g/dL (range 6.9–14.4), respectively. A significant increase was seen in the Hb and KPS score (
p |
| doi_str_mv | 10.1016/S0360-3016(02)03823-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72939158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301602038233</els_id><sourcerecordid>72939158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-bea36fcc91e23897300fb742c8d62c3b9490b29a3a4e66c4919579cd850c48b33</originalsourceid><addsrcrecordid>eNqFkEtv1DAURi0EokPhJ4CyAcEi4FceXlWo4lGpEgtAYmc5NzcdoyQO106l2fHTcToDXbKyZZ_P3_Vh7LngbwUX9buvXNW8VHn7mss3XLVSleoB24m2MaWqqh8P2e4fcsaexPiTcy5Eox-zMyErrrlWO_b7aloo3OKEcyr8XCxIQ6DJzYBFTC6tsXBDQiqQDmlPYQkeU-YSoUt_Q-M63xSwZahYXPL5OBbr3CPdBL9dhRlWoo2GPU6BXO9D2iO55fCUPRrcGPHZaT1n3z9--Hb5ubz-8unq8v11CcqIVHboVD0AGIFStaZRnA9doyW0fS1BdUYb3knjlNNY16CNMFVjoG8rDrrtlDpnr47v5u_-WjEmO_kIOI5uxrBG20iTi6o2g9URBAoxEg52IT85OljB7abe3qm3m1fLpb1Tb7eCF6eCtZuwv0-dXGfg5QlwEdw4UBbm4z2ntZam0Zm7OHKYddx6JBshKwXsPSEk2wf_n1H-AH9Ko-0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72939158</pqid></control><display><type>article</type><title>Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Casas, Francesc ; Viñolas, Núria ; Ferrer, Ferran ; Farrús, Blanca ; Gimferrer, Josep Maria ; Agustı́, Carles ; Belda, Josep ; Luburich, Patricio</creator><creatorcontrib>Casas, Francesc ; Viñolas, Núria ; Ferrer, Ferran ; Farrús, Blanca ; Gimferrer, Josep Maria ; Agustı́, Carles ; Belda, Josep ; Luburich, Patricio</creatorcontrib><description>Purpose
: A prospective Phase II trial was carried out to evaluate the effectiveness of erythropoietin in improving or maintaining performance status as determined by the Karnofsky performance status (KPS) score and hemoglobin (Hb) levels in lung cancer patients treated with concurrent chemoradiation (CH-RT).
Methods and Materials
: A total of 51 patients with lung cancer (11 with small-cell, limited stage and 40 with non-small-cell disease, 17 with Stage IIIA and 23 with Stage IIIB), who underwent three different concurrent CH-RT protocols were enrolled. Baseline Hb and KPS values were recorded, as were the nadir Hb and KPS values before concurrent CH-RT. The final Hb and KPS values were recorded the last week of concurrent CH-RT. An Hb level of ≤11 g/dL before concurrent CH-RT was required before receiving erythropoietin. Prognostic factors for KPS improvement and survival were assessed by univariate and multivariate studies.
Results
: Of the 51 patients, 47 (92.3%) were men (mean age 63.6 years, range 40–75). The median baseline KPS score was 80, and the mean baseline Hb was 12.2 ± 1.76 g/dL (range 9–16.9). The mean nadir and final Hb value was 9.98 ± 0.67 g/dL (range 8.6–11) and 11.33 ± 1.59 g/dL (range 6.9–14.4), respectively. A significant increase was seen in the Hb and KPS score (
p <0.05) in the final measurements. Differences were found between the final and nadir Hb in the predictive value for differences in performance status (
p = 0.001). On univariate study, pathologic findings (
p = 0.0234), weight loss (
p = 0.0049), baseline Hb (
p = 0.0057), and final Hb improvement (
p = 0.0237) were prognostic factors for survival. Nadir Hb (
p = 0.027), final Hb improvement (
p = 0.0069), pathologic findings (
p = 0.0006), and weight loss (
p = 0.0001) had significant prognostic value for survival in multivariate analysis.
Conclusion
: In this study, erythropoietin appears to have a significant, beneficial impact on the KPS and Hb of patients undergoing concurrent CH-RT.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/S0360-3016(02)03823-3</identifier><identifier>PMID: 12504043</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Aged ; Anemia ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Chemoradiation ; Combined Modality Therapy ; Combined treatment ; Erythropoietin ; Erythropoietin - therapeutic use ; Female ; Hemoglobins - analysis ; Humans ; Karnofsky performance status score ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Quality of Life ; Recombinant Proteins ; Survival Rate ; Treatment. General aspects ; Tumors</subject><ispartof>International journal of radiation oncology, biology, physics, 2003, Vol.55 (1), p.116-124</ispartof><rights>2003 Elsevier Science Inc.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-bea36fcc91e23897300fb742c8d62c3b9490b29a3a4e66c4919579cd850c48b33</citedby><cites>FETCH-LOGICAL-c391t-bea36fcc91e23897300fb742c8d62c3b9490b29a3a4e66c4919579cd850c48b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301602038233$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14442974$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12504043$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Casas, Francesc</creatorcontrib><creatorcontrib>Viñolas, Núria</creatorcontrib><creatorcontrib>Ferrer, Ferran</creatorcontrib><creatorcontrib>Farrús, Blanca</creatorcontrib><creatorcontrib>Gimferrer, Josep Maria</creatorcontrib><creatorcontrib>Agustı́, Carles</creatorcontrib><creatorcontrib>Belda, Josep</creatorcontrib><creatorcontrib>Luburich, Patricio</creatorcontrib><title>Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose
: A prospective Phase II trial was carried out to evaluate the effectiveness of erythropoietin in improving or maintaining performance status as determined by the Karnofsky performance status (KPS) score and hemoglobin (Hb) levels in lung cancer patients treated with concurrent chemoradiation (CH-RT).
Methods and Materials
: A total of 51 patients with lung cancer (11 with small-cell, limited stage and 40 with non-small-cell disease, 17 with Stage IIIA and 23 with Stage IIIB), who underwent three different concurrent CH-RT protocols were enrolled. Baseline Hb and KPS values were recorded, as were the nadir Hb and KPS values before concurrent CH-RT. The final Hb and KPS values were recorded the last week of concurrent CH-RT. An Hb level of ≤11 g/dL before concurrent CH-RT was required before receiving erythropoietin. Prognostic factors for KPS improvement and survival were assessed by univariate and multivariate studies.
Results
: Of the 51 patients, 47 (92.3%) were men (mean age 63.6 years, range 40–75). The median baseline KPS score was 80, and the mean baseline Hb was 12.2 ± 1.76 g/dL (range 9–16.9). The mean nadir and final Hb value was 9.98 ± 0.67 g/dL (range 8.6–11) and 11.33 ± 1.59 g/dL (range 6.9–14.4), respectively. A significant increase was seen in the Hb and KPS score (
p <0.05) in the final measurements. Differences were found between the final and nadir Hb in the predictive value for differences in performance status (
p = 0.001). On univariate study, pathologic findings (
p = 0.0234), weight loss (
p = 0.0049), baseline Hb (
p = 0.0057), and final Hb improvement (
p = 0.0237) were prognostic factors for survival. Nadir Hb (
p = 0.027), final Hb improvement (
p = 0.0069), pathologic findings (
p = 0.0006), and weight loss (
p = 0.0001) had significant prognostic value for survival in multivariate analysis.
Conclusion
: In this study, erythropoietin appears to have a significant, beneficial impact on the KPS and Hb of patients undergoing concurrent CH-RT.</description><subject>Adult</subject><subject>Aged</subject><subject>Anemia</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Chemoradiation</subject><subject>Combined Modality Therapy</subject><subject>Combined treatment</subject><subject>Erythropoietin</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Karnofsky performance status score</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Survival Rate</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtv1DAURi0EokPhJ4CyAcEi4FceXlWo4lGpEgtAYmc5NzcdoyQO106l2fHTcToDXbKyZZ_P3_Vh7LngbwUX9buvXNW8VHn7mss3XLVSleoB24m2MaWqqh8P2e4fcsaexPiTcy5Eox-zMyErrrlWO_b7aloo3OKEcyr8XCxIQ6DJzYBFTC6tsXBDQiqQDmlPYQkeU-YSoUt_Q-M63xSwZahYXPL5OBbr3CPdBL9dhRlWoo2GPU6BXO9D2iO55fCUPRrcGPHZaT1n3z9--Hb5ubz-8unq8v11CcqIVHboVD0AGIFStaZRnA9doyW0fS1BdUYb3knjlNNY16CNMFVjoG8rDrrtlDpnr47v5u_-WjEmO_kIOI5uxrBG20iTi6o2g9URBAoxEg52IT85OljB7abe3qm3m1fLpb1Tb7eCF6eCtZuwv0-dXGfg5QlwEdw4UBbm4z2ntZam0Zm7OHKYddx6JBshKwXsPSEk2wf_n1H-AH9Ko-0</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Casas, Francesc</creator><creator>Viñolas, Núria</creator><creator>Ferrer, Ferran</creator><creator>Farrús, Blanca</creator><creator>Gimferrer, Josep Maria</creator><creator>Agustı́, Carles</creator><creator>Belda, Josep</creator><creator>Luburich, Patricio</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2003</creationdate><title>Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy</title><author>Casas, Francesc ; Viñolas, Núria ; Ferrer, Ferran ; Farrús, Blanca ; Gimferrer, Josep Maria ; Agustı́, Carles ; Belda, Josep ; Luburich, Patricio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-bea36fcc91e23897300fb742c8d62c3b9490b29a3a4e66c4919579cd850c48b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anemia</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Chemoradiation</topic><topic>Combined Modality Therapy</topic><topic>Combined treatment</topic><topic>Erythropoietin</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Karnofsky performance status score</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Survival Rate</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Casas, Francesc</creatorcontrib><creatorcontrib>Viñolas, Núria</creatorcontrib><creatorcontrib>Ferrer, Ferran</creatorcontrib><creatorcontrib>Farrús, Blanca</creatorcontrib><creatorcontrib>Gimferrer, Josep Maria</creatorcontrib><creatorcontrib>Agustı́, Carles</creatorcontrib><creatorcontrib>Belda, Josep</creatorcontrib><creatorcontrib>Luburich, Patricio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Casas, Francesc</au><au>Viñolas, Núria</au><au>Ferrer, Ferran</au><au>Farrús, Blanca</au><au>Gimferrer, Josep Maria</au><au>Agustı́, Carles</au><au>Belda, Josep</au><au>Luburich, Patricio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2003</date><risdate>2003</risdate><volume>55</volume><issue>1</issue><spage>116</spage><epage>124</epage><pages>116-124</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose
: A prospective Phase II trial was carried out to evaluate the effectiveness of erythropoietin in improving or maintaining performance status as determined by the Karnofsky performance status (KPS) score and hemoglobin (Hb) levels in lung cancer patients treated with concurrent chemoradiation (CH-RT).
Methods and Materials
: A total of 51 patients with lung cancer (11 with small-cell, limited stage and 40 with non-small-cell disease, 17 with Stage IIIA and 23 with Stage IIIB), who underwent three different concurrent CH-RT protocols were enrolled. Baseline Hb and KPS values were recorded, as were the nadir Hb and KPS values before concurrent CH-RT. The final Hb and KPS values were recorded the last week of concurrent CH-RT. An Hb level of ≤11 g/dL before concurrent CH-RT was required before receiving erythropoietin. Prognostic factors for KPS improvement and survival were assessed by univariate and multivariate studies.
Results
: Of the 51 patients, 47 (92.3%) were men (mean age 63.6 years, range 40–75). The median baseline KPS score was 80, and the mean baseline Hb was 12.2 ± 1.76 g/dL (range 9–16.9). The mean nadir and final Hb value was 9.98 ± 0.67 g/dL (range 8.6–11) and 11.33 ± 1.59 g/dL (range 6.9–14.4), respectively. A significant increase was seen in the Hb and KPS score (
p <0.05) in the final measurements. Differences were found between the final and nadir Hb in the predictive value for differences in performance status (
p = 0.001). On univariate study, pathologic findings (
p = 0.0234), weight loss (
p = 0.0049), baseline Hb (
p = 0.0057), and final Hb improvement (
p = 0.0237) were prognostic factors for survival. Nadir Hb (
p = 0.027), final Hb improvement (
p = 0.0069), pathologic findings (
p = 0.0006), and weight loss (
p = 0.0001) had significant prognostic value for survival in multivariate analysis.
Conclusion
: In this study, erythropoietin appears to have a significant, beneficial impact on the KPS and Hb of patients undergoing concurrent CH-RT.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12504043</pmid><doi>10.1016/S0360-3016(02)03823-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2003, Vol.55 (1), p.116-124 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72939158 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anemia Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Chemoradiation Combined Modality Therapy Combined treatment Erythropoietin Erythropoietin - therapeutic use Female Hemoglobins - analysis Humans Karnofsky performance status score Lung cancer Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Quality of Life Recombinant Proteins Survival Rate Treatment. General aspects Tumors |
| title | Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A43%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20in%20performance%20status%20after%20erythropoietin%20treatment%20in%20lung%20cancer%20patients%20undergoing%20concurrent%20chemoradiotherapy&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Casas,%20Francesc&rft.date=2003&rft.volume=55&rft.issue=1&rft.spage=116&rft.epage=124&rft.pages=116-124&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/S0360-3016(02)03823-3&rft_dat=%3Cproquest_cross%3E72939158%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72939158&rft_id=info:pmid/12504043&rft_els_id=S0360301602038233&rfr_iscdi=true |